Results 51 to 60 of about 3,808 (77)

A Novel Dual Bruton's Tyrosine Kinase/Janus Kinase 3 Inhibitor Wj1113 and its Therapeutic Effects on Rheumatoid Arthritis. [PDF]

MedComm (2020)
Zhang C, Lai F, Gong H, Li S, Xiang N, Que L, Xue N, Hao M, Zhou E, Wang X, Liang T, Jin J.   +11 more
europepmc   +1 more source

Bruton's tyrosine kinase inhibitors in diffuse large B-cell lymphoma therapy: critical considerations and future innovations. [PDF]

J Transl Med
Lu C, Chen Q, Shen Y, Chen M, Xie Y, Wang C, Yu L.   +6 more
europepmc   +1 more source

Expression of Bruton's Tyrosine Kinase Reflects Immune Cells Infiltration and Cell Proliferation in Breast Cancer. [PDF]

World J Oncol
AlRammah T, Wu R, Chida K, Kawashima K, Hakamada K, Ishikawa T, Ebos JML, Takabe K.   +7 more
europepmc   +1 more source

A pharmacovigilance study of Bruton's tyrosine kinase inhibitors: a multidimensional analysis based on FAERS and VigiBase. [PDF]

Front Immunol
Qu H, Jia Y, Liu Z, Li Z, Zhao X, Wu Z, Fan G, Lou Y.   +7 more
europepmc   +1 more source

Case Report: Secondary neurolymphomatosis successfully treated with sequential Bruton's tyrosine kinase inhibitor and bispecific antibody therapy. [PDF]

Front Oncol
Oura M, Toho M, Ikeda D, Fukuda N, Torres AS, Fujii F, Sakuma H, Uehara A, Tabata R, Narita K, Takeuchi M, Matsue K.   +11 more
europepmc   +1 more source

Covalent Bruton's tyrosine kinase inhibitor HZ-A-018 in patients with relapsed or refractory B cell malignancies: A multicenter phase I study. [PDF]

iScience
Wu G, Wei J, Yang H, Fan L, Yu S, Zhang J, Lin M, Zhou H, Xu N, Hu M, Zhou X, Jin J, Qian W, Shentu J.   +13 more
europepmc   +1 more source

UVI5008: the first reversible, non-covalent Bruton's tyrosine kinase epi-inhibitor for B-cell malignancies. [PDF]

J Hematol Oncol
Dell'Aversana C, Sgueglia G, Massaro C, Perricone U, Sarno F, Megchelenbrink WL, Conte M, Carafa V, Campanella A, Frenquelli M, Bordini J, Ghia P, Petrizzi VB, Alvarez R, Nappi D, Chiurazzi F, Tambaro FP, Wierda WG, de Lera AR, Altucci L.   +19 more
europepmc   +1 more source

Comparing novel treatments in chronic spontaneous urticaria: A critical appraisal of Bruton's tyrosine kinase inhibitors versus anti-cytokine biologics in clinical trials. [PDF]

Clin Transl Allergy
Diamanti A, Tontini C, Bulfone-Paus S.
europepmc   +1 more source

Leveraging Kinase Drugs for Neurosciences: Discovery of Selective, CNS-Penetrant Reversible Bruton's Tyrosine Kinase Inhibitors as Therapeutics for Neuroinflammation. [PDF]

J Med Chem
Hopkins BT, Marx IE, Vandeveer HG, Nevalainen M, Basile R, Bajrami B, Choi CK, Grater RJ, Gu C, Hoemberger M, Kadakia E, Kapadnis SK, Liu Y, Ma B, Magee T, Metrick CM, Mingueneau M, Muste CA, Parker Harp CR, Prince RJ, Santoro JC, Schulz J, Sciabola S, Tang H, Wang T, Meissner R, Bohnert T.   +26 more
europepmc   +1 more source

Discovery of novel acridine based inhibitors of Bruton's tyrosine kinase (BTK) via pharmacophore modeling and machine learning-driven virtual screening followed by molecular dynamic studies. [PDF]

J Comput Aided Mol Des
Shahin R, Jaafreh S, Mansi I, Al Zoubi R, Abu-Irmaileh B, Azzam Y, Azzam S.   +6 more
europepmc   +1 more source